Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Express Scripts
Cerilliant
Teva
Moodys
Boehringer Ingelheim
Colorcon
McKesson

Generated: July 21, 2018

DrugPatentWatch Database Preview

Ge Healthcare Company Profile

« Back to Dashboard

Summary for Ge Healthcare
International Patents:113
US Patents:7
Tradenames:62
Ingredients:42
NDAs:54
Drug Master File Entries: 5
Patent Litigation for Ge Healthcare: See patent lawsuits for Ge Healthcare

Drugs and US Patents for Ge Healthcare

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare MYOVIEW technetium tc-99m tetrofosmin kit INJECTABLE;INJECTION 020372-001 Feb 9, 1996 DISCN Yes No ➤ Sign Up ➤ Sign Up
Ge Healthcare SODIUM IODIDE I 123 sodium iodide i-123 CAPSULE;ORAL 017630-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Ge Healthcare OMNIPAQUE 12 iohexol SOLUTION;ORAL 018956-009 Apr 17, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up
Ge Healthcare HYPAQUE diatrizoate meglumine INJECTABLE;INJECTION 016403-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Ge Healthcare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ge Healthcare OMNIPAQUE 240 iohexol SOLUTION;INJECTION, ORAL, RECTAL 018956-002 Dec 26, 1985 4,396,597 ➤ Sign Up
Ge Healthcare OMNIPAQUE 140 iohexol INJECTABLE;INJECTION 018956-005 Nov 30, 1988 4,250,113 ➤ Sign Up
Ge Healthcare VISIPAQUE 320 iodixanol INJECTABLE;INJECTION 020351-002 Mar 22, 1996 RE36418 ➤ Sign Up
Ge Healthcare OPTISON albumin human INJECTABLE;INJECTION 020899-001 Dec 31, 1997 5,529,766 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Ge Healthcare

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,854,920 Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition ➤ Sign Up
5,558,854 Ultrasound contrast media comprising perfluoropentane and perfluorohexane gas ➤ Sign Up
5,573,751 Persistent gaseous bubbles as ultrasound contrast media ➤ Sign Up
9,833,458 Thioflavin derivatives for use in the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Ge Healthcare Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB03/033 United Kingdom ➤ Sign Up PRODUCT NAME: ROSUVASTATIN OPTIONALLY IN THE FORM OF A NON-TOXIC PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY THE CALCIUM SALT.; REGISTERED: NL 26872 20021106; NL 26873 20021106; NL 26874 20021106; UK PL 17901/0201 20030321; UK PL 17901/0202 20030321; UK PL 17901/0203 20030321
2009 00036 Denmark ➤ Sign Up PRODUCT NAME: PACLITAXELALBUMIN
C/GB07/011 United Kingdom ➤ Sign Up PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003
15/005 Ireland ➤ Sign Up PRODUCT NAME: VIZAMYL-FLUTEMETAMOL (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
US Army
McKesson
Dow
Chinese Patent Office
Healthtrust
Accenture
Express Scripts
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.